Could a common antibiotic boost eczema treatment?
NCT ID NCT07713186
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This trial investigates whether adding the antibiotic azithromycin to standard topical creams (betamethasone or tacrolimus) improves eczema symptoms in children aged 3 to 12 with mild to moderate atopic dermatitis. Researchers will measure changes in the Eczema Area and Severity Index (EASI) score over 8 weeks. The goal is to see if the combination works better than creams alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- azithromycin added to betamethasone or tacrolimus ointments
- What this could lead to
- If adding azithromycin works, it could offer a simple, low-cost way to boost the effectiveness of standard eczema creams.
- What could go wrong
- This is a small, early-phase trial with only 40 children, so results may not apply broadly. Azithromycin can cause side effects like stomach upset or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
3 to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Both genders, ages from 3 to 12 years old with mild to moderate atopic dermatitis Exclusion Criteria: * Atopic dermatitis on active systemic treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cairo University
Cairo, Saray, 11562, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an eczema drug reshape the Skin's microbial community?
- Can a pill tame severe eczema? a new trial puts QX-4533 to the test
- Can a probiotic soothe Children's eczema?
- Could junk food fuel eczema in kids?
- Can a daily pill calm severe eczema from the inside?
- Can we predict the path of chronic skin disease?